{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:16:34Z","timestamp":1761920194171,"version":"build-2065373602"},"reference-count":28,"publisher":"Index Copernicus","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol Przegl Chir"],"published-print":{"date-parts":[[2025,5,14]]},"abstract":"<ns3:p>&lt;b&gt;Introduction:&lt;\/b&gt; Dupuytren's disease is a common condition of the palmar aponeurosis, leding to contractures of the fingers. The disease onset is the formation of nodules in the palmar aponeurosis, which can be painful in some patients. Resection of the affected part of the palmar aponeurosis and release of finger contracture is a method of treating the advanced form of the disease, while in the early phase, awaiting progression has so far been recommended. Research presented over the past few years indicates the possibility of active treatment of early Dupuytren's disease to prevent the development of contractures.&lt;b&gt;Aim:&lt;\/b&gt; The aim of this article was a review of treatment modalities in the early Dupuytren\u2019s disease, mainly in terms of their efficacy, safety, and future perspectives.&lt;b&gt;Methods:&lt;\/b&gt; The current literature focusing on treatment modalities in early-stage Dupuytren\u2019s disease was reviewed.&lt;b&gt;Results:&lt;\/b&gt; To treat the early stage of the disease, various substances such as steroids, monoclonal antibodies, and &lt;i&gt;Clostridium histolyticum&lt;\/i&gt; collagenase were injected into the nodules. Radiotherapy and various methods of physical therapy were also used. The effectiveness of all these techniques was limited, although some, such as anti-TNF monoclonal antibody and radiotherapy, showed the ability to inhibit disease progression.&lt;b&gt;Conclusions:&lt;\/b&gt; Results of reviewed studies show that active treatment of the early stage of Dupuytren\u2019s disease has thepotential to prevent progression of finger contractures.<\/ns3:p>","DOI":"10.5604\/01.3001.0055.1317","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T06:26:18Z","timestamp":1747722378000},"page":"57-63","source":"Crossref","is-referenced-by-count":0,"title":["Management of early stages of Dupuytren\u2019s disease: a narrative review"],"prefix":"10.5604","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-2488","authenticated-orcid":false,"given":"Andrzej","family":"\u017byluk","sequence":"first","affiliation":[{"name":"Department of General and Hand Surgery, Pomeranian Medical University in Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3689","reference":[{"key":"629550r1","unstructured":"Bayat A.: Cell biology and Dupuytren\u2019s disease. In: Dupuytren\u2019s disease. FESSHInstructional Course, ed.: Warwick D., CG Edizioni Medico Scientifiche, Torino 2015, 30\u201336."},{"key":"629550r2","doi-asserted-by":"crossref","unstructured":"Hart M.G., Hooper G.: Clinical associations of Dupuytren\u2019s disease. PostgradMed J., 2005; 81(957): 425\u2013428. doi: 10.1136\/pgmj.2004.027425.","DOI":"10.1136\/pgmj.2004.027425"},{"key":"629550r3","doi-asserted-by":"crossref","unstructured":"Ruettermann M., Hermann R.M., Khatib-Chahidi K., Werker P.M.N.: Dupuytren\u2019s Disease-Etiology and Treatment. Dtsch Arztebl Int., 2021; 118(46):781\u2013788. doi: 10.3238\/arztebl.m2021.0325.","DOI":"10.3238\/arztebl.m2021.0325"},{"key":"629550r4","unstructured":"\u017byluk A.: Genetyczna sk\u0142onno\u015b\u0107 do choroby Dupuytrena: przegl\u0105d pi\u015bmiennictwa. Pol Przegl Chir., 2008; 80: 162\u2013169."},{"key":"629550r5","unstructured":"Dias J.: Dupuytren\u2019s contracture: recurrence, unanswered questions and costs. In: Dupuytren\u2019s disease. FESSH Instructional Course, ed.: Warwick D., CGEdizioni Medico Scientifiche, Torino 2015, 227\u2013236."},{"key":"629550r6","doi-asserted-by":"crossref","unstructured":"Tajika T., Kobayashi T., Kaneko T. et al: Epidemiological study for personal riskfactors and quality of life related to Dupuytren\u2019s disease in a mountain villageof Japan. J Orthop Sci., 2014; 19(1): 64\u201370. doi: 10.1007\/s00776-013-0478-y.","DOI":"10.1007\/s00776-013-0478-y"},{"key":"629550r7","doi-asserted-by":"crossref","unstructured":"\u017byluk A.: Dupuytren\u2019s disease \u2013 what\u2019s new: a review. Pol Przegl Chir., 2022;95(6): 53\u201361. doi: 10.5604\/01.3001.0016.0058.","DOI":"10.5604\/01.3001.0016.0058"},{"key":"629550r8","doi-asserted-by":"crossref","unstructured":"Lanting R., van den Heuvel E.R., Werker P.M.: Clusters in Short-term DiseaseCourse in Participants With Primary Dupuytren Disease. J Hand Surg Am.,2016; 41(3): 354\u2013361. doi: 10.1016\/j.jhsa.2015.10.027.","DOI":"10.1016\/j.jhsa.2015.10.027"},{"key":"629550r9","doi-asserted-by":"crossref","unstructured":"Costas B., Coleman S., Kaufman G. et al.: Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: a randomizedcontrolled trial. BMC Musculoskelet Disord., 2017; 18(1): 374. doi: 10.1186\/s12891-017-1713-z.","DOI":"10.1186\/s12891-017-1713-z"},{"key":"629550r10","doi-asserted-by":"crossref","unstructured":"Ball C., Izadi D., Verjee L.S., Chan J., Nanchahal J.: Systematic review of non--surgical treatments for early dupuytren\u2019s disease. BMC Musculoskelet Disord.2016; 17(1): 345. doi: 10.1186\/s12891-016-1200-y.","DOI":"10.1186\/s12891-016-1200-y"},{"key":"629550r11","doi-asserted-by":"crossref","unstructured":"Fernando J.J., Fowler C., Graham T. et al.: Pre-operative hand therapy management of Dupuytren\u2019s disease: A systematic review. Hand Ther., 2024; 29(2):52\u201361. doi: 10.1177\/17589983241227162.","DOI":"10.1177\/17589983241227162"},{"key":"629550r12","doi-asserted-by":"crossref","unstructured":"Ketchum L.D., Donahue T.K.: The injection of nodules of Dupuytren\u2019s diseasewith triamcinolone acetonide. J Hand Surg Am., 2000; 25(6): 1157\u20131162. doi:10.1053\/jhsu.2000.18493.","DOI":"10.1053\/jhsu.2000.18493"},{"key":"629550r13","doi-asserted-by":"crossref","unstructured":"Yin C.Y., Yu H.M., Wang J.P. et al.: Long-term follow-up of Dupuytren disease after injection of triamcinolone acetonide in Chinese patients in Taiwan.J Hand Surg Eur Vol., 2017; 42(7): 678\u2013682. doi: 10.1177\/1753193417690961.","DOI":"10.1177\/1753193417690961"},{"key":"629550r14","doi-asserted-by":"crossref","unstructured":"Nanchahal J., Chan J.K.: Treatments for early-stage Dupuytren\u2019s disease: anevidence-based approach. J Hand Surg Eur Vol., 2023; 48(3): 191\u2013198. doi:10.1177\/17531934221131373.","DOI":"10.1177\/17531934221131373"},{"key":"629550r15","doi-asserted-by":"crossref","unstructured":"Lambi A.G., Popoff S.N., Benhaim P., Barbe M.F.: Pharmacotherapies in Dupuytren\u2019s Disease: Current and Novel Strategies. J Hand Surg Am., 2023; 48(8):810\u2013821. doi: 10.1016\/j.jhsa.2023.02.003.","DOI":"10.1016\/j.jhsa.2023.02.003"},{"key":"629550r16","doi-asserted-by":"crossref","unstructured":"Verjee L.S., Verhoekx J.S., Chan J.K. et al.: Unraveling the signaling pathways promoting fibrosis in Dupuytren\u2019s disease reveals TNF as a therapeutic target. ProcNatl Acad Sci U S A., 2013; 110(10): E928\u2013937. doi: 10.1073\/pnas.1301100110.","DOI":"10.1073\/pnas.1301100110"},{"key":"629550r17","doi-asserted-by":"crossref","unstructured":"Nanchahal J., Ball C., Davidson D. et al.: Anti-Tumour Necrosis Factor Therapy for Dupuytren\u2019s Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial. EBioMedicine., 2018; 33: 282\u2013288. doi: 10.1016\/j.ebiom.2018.06.022.","DOI":"10.1016\/j.ebiom.2018.06.022"},{"key":"629550r18","doi-asserted-by":"crossref","unstructured":"Dakin H., Rombach I., Dritsaki M. et al.: Cost-effectiveness of adalimumabfor early-stage Dupuytren\u2019s disease: an economic evaluation based on a randomized controlled trial and individual-patient simulation model. Bone JtOpen., 2022; 3(11): 898\u2013906. doi: 10.1302\/2633-1462.311.BJO-2022-0103.R2.","DOI":"10.1302\/2633-1462.311.BJO-2022-0103.R2"},{"key":"629550r19","doi-asserted-by":"crossref","unstructured":"Badalamente M.A., Sampson S.P., Hurst L.C., Dowd A., Miyasaka K.: The roleof transforming growth factor beta in Dupuytren\u2019s disease. J Hand Surg Am.,1996; 21(2): 210\u2013215. doi: 10.1016\/S0363-5023(96)80102-X.","DOI":"10.1016\/S0363-5023(96)80102-X"},{"key":"629550r20","doi-asserted-by":"crossref","unstructured":"Bisson M.A., McGrouther D.A., Mudera V., Grobbelaar A.O.: The differentcharacteristics of Dupuytren\u2019s disease fibroblasts derived from either nodule or cord: expression of alpha-smooth muscle actin and the response to stimulation by TGF-beta1. J Hand Surg Br., 2003; 28(4): 351\u2013356. doi: 10.1016\/s0266-7681(03)00135-9.","DOI":"10.1016\/S0266-7681(03)00135-9"},{"key":"629550r21","doi-asserted-by":"crossref","unstructured":"Panigrahi S., Barry A., Multner S. et al.: Pirfenidone as a potential antifibroticinjectable for Dupuytren\u2019s disease. Pharm Dev Technol., 2022; 27(2): 242\u2013250.doi: 10.1080\/10837450.2022.2038201.","DOI":"10.1080\/10837450.2022.2038201"},{"key":"629550r22","doi-asserted-by":"crossref","unstructured":"Adamietz B., Keilholz L., Gr\u00fcnert J., Sauer R.: Radiotherapy of early stageDupuytren disease. Long-term results after a median follow-up period of 10 years. Strahlenther Onkol., 2001; 177(11): 604\u2013610. doi: 10.1007\/pl00002371.","DOI":"10.1007\/PL00002371"},{"key":"629550r23","unstructured":"Weinzierl G., Fl\u00fcgel M., Geldmacher J.: Lack of effectiveness of alternative non-surgical treatment procedures of Dupuytren contracture. Chirurg.,1993; 64(6): 492\u2013494."},{"key":"629550r24","doi-asserted-by":"crossref","unstructured":"Fernando J.J., Fowler C., Graham T. et al.: Pre-operative hand therapy management of Dupuytren\u2019s disease: A systematic review. Hand Ther., 2024; 29(2):52\u201361. doi: 10.1177\/17589983241227162.","DOI":"10.1177\/17589983241227162"},{"key":"629550r25","doi-asserted-by":"crossref","unstructured":"Larocerie-Salgado J., Davidson J.: Nonoperative treatment of PIPJ flexioncontractures associated with Dupuytren\u2019s disease. J Hand Surg Eur Vol., 2012;37(8): 722\u2013727. doi: 10.1177\/1753193411422680.","DOI":"10.1177\/1753193411422680"},{"key":"629550r26","doi-asserted-by":"crossref","unstructured":"Christie W.S., Puhl A.A., Lucaciu O.C.: Cross-frictional therapy and stretching for the treatment of palmar adhesions due to Dupuytren\u2019s contracture: a prospective case study. Man Ther., 2012; 17(5): 479\u2013482. doi: 10.1016\/j.math.2011.11.001.","DOI":"10.1016\/j.math.2011.11.001"},{"key":"629550r27","doi-asserted-by":"crossref","unstructured":"Knobloch K., Hellweg M., Sorg H., Nedelka T.: Focused electromagnetic high--energetic extracorporeal shockwave (ESWT) reduces pain levels in the nodular state of Dupuytren\u2019s disease-a randomized controlled trial (DupuyShock).Lasers Med Sci., 2022; 37(1): 323\u2013333. doi: 10.1007\/s10103-021-03254-9.","DOI":"10.1007\/s10103-021-03254-9"},{"key":"629550r28","unstructured":"Notarnicola A., Maccagnano G., Rifino F. et al.: Short-term effect of shockwavetherapy, temperature controlled high energy adjustable multi-mode emissionlaser or stretching in Dupuytren\u2019s disease: a prospective randomized clinicaltrial. J Biol Regul Homeost Agents., 2017; 31(3): 775\u2013784."}],"container-title":["Polish Journal of Surgery"],"original-title":[],"link":[{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0055.1317","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0055.1317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:11:21Z","timestamp":1761919881000},"score":1,"resource":{"primary":{"URL":"https:\/\/ppch.pl\/gicid\/01.3001.0055.1317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.5604\/01.3001.0055.1317","relation":{},"ISSN":["0032-373X","2299-2847"],"issn-type":[{"type":"print","value":"0032-373X"},{"type":"electronic","value":"2299-2847"}],"subject":[],"published":{"date-parts":[[2025,5,14]]}}}